FILTER

FILTERED INTERVIEW RESULTS

Katrin Rupalla

CEO, YMMUNOBIO
"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200, we have obtained orphan drug status from FDA for the treatment of liver cancer."

Stefan Randl & Paul Spencer

HEAD OF DRUG SUBSTANCE (SR), HEAD OF DRUG DELIVERY & PRODUCT (PS), EVONIK HEALTH CARE
"The US leads innovation, so if you are not heavily invested there in pharma, you are in trouble. Lots of our clients are shifting their production from Asia, so the US will remain critical to Evonik Health Care’s growth."

Roger Erickson

CEO AND FOUNDER, INTERBIOME
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."

Jan Kengelbach

CEO, AENOVA GROUP
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."

Donna LaVoie

PRESIDENT AND CEO, LAVOIEHEALTHSCIENCE
"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."

Daniel Prince

CEO, PRINCE STERILIZATION SERVICES
"The expansion will allow Prince to more than double its headcount, increase manufacturing capacity, and offer additional ready-to-use products and sterilization services to the market."

Tom Sellig

CEO, ADARE PHARMA SOLUTIONS
"For every challenge, we have a set of tools we can leverage to create optimized solutions beyond taste masking."

Louis Kassa

PRESIDENT AND CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"I hope to continue seeing companies coming from across the country contributing to the significant growth of the greater Philadelphia area in life sciences."

Denis Dufrane

CO-FOUNDER AND CEO, NOVADIP
"I believe 2023 and 2024 will be key for Novadip. We have already closed two trials in the autologous program. We are now in Phase 1/2 trials for CPT in young patients, both in the US and in Europe."

Jeff Butler

PRESIDENT, AMPAC FINE CHEMICALS
"AFC’s core technology differentiators include energetic chemistry, high potency manufacturing, and extensive chromatographic separation capabilities."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS